If You Were Prescribed Oxbryta to Treat Sickle Cell Disease, You May be Entitled to Significant Compensation.

See If You Qualify for Compensation Now!

• Oxbryta, a Sickle Cell Disease treatment, was recalled by the FDA due to studies showing an increased risk of vaso-occlusive crisis, stroke, organ failure, or death.
• Post-marketing studies revealed increased vaso-occlusive crises and higher mortality rates in users, leading Pfizer to determine that risks outweigh benefits.

Class Action Lawsuit for Oxbryta Users Facing Life-Threatening Complications

If you or a loved one were prescribed Oxbryta for sickle cell disease and experienced serious medical complications, you may qualify for a class action lawsuit investigation. Since its 2019 release, Oxbryta was hailed as a promising treatment to manage sickle cell symptoms. However, recent studies have raised safety concerns, revealing that it may increase the risk of vaso-occlusive crises, which can block blood flow to vital organs and result in severe pain or fatal outcomes. Those affected may be eligible for compensation for medical expenses, lost income, and suffering.

Pfizer Withdraws Oxbryta Following Reports of Severe Side Effects

Pfizer has announced the withdrawal of Oxbryta, its treatment for sickle cell disease, amid concerning reports of severe pain and fatalities associated with the drug. Patients are advised by Pfizer, the FDA, and the European Medicines Agency to consult their prescribing physician if they are currently using Oxbryta. Originally designed to treat hemolytic anemia related to sickle cell disease, recent registry studies have identified serious side effects, including an increase in “vaso-occlusive crises.”